Physician profile
Robert D Siew
NPI 1578539516
$2,596.55
in general payments reported to CMS, 2019-2025
23 companies · $281 in 2025
The $281 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $626 · 2020: $509 · 2021: $510 · 2022: $237 · 2023: $94.93 · 2024: $338 · 2025: $281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $714.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $713.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $862.67 | 2019-2025 | Trelegy Ellipta, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $559.14 | 2019-2023 | Spiriva Respimat, Stiolto Respimat |
| Teleflex LLC | $162.67 | 2024 | Urolift |
| Mylan Specialty L.P. | $144.41 | 2019-2024 | Yupelri |
| Merck Sharp & Dohme LLC | $123.38 | 2019-2020 | |
| Edwards Lifesciences Corporation | $116.58 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $87.62 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $84.11 | 2019-2021 | |
| Verona Pharma, INC. | $55.75 | 2025 | Ohtuvayre |
| Advanced Respiratory, INC | $55.53 | 2019-2021 | |
| Shionogi INC | $55.21 | 2022 | |
| Genzyme Corporation | $48.41 | 2020 | |
| Pulmonx Corporation | $43.58 | 2025 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Amgen INC. | $32.64 | 2019 | |
| United Therapeutics Corporation | $25.58 | 2024 | Tyvaso |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $22.82 | 2019 | |
| Sunovion Pharmaceuticals INC. | $22.68 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $21.45 | 2025 | Uptravi, Opsumit |
| Janssen Pharmaceuticals, INC | $17.69 | 2022 | |
| Lilly USA, LLC | $16.50 | 2025 | Zepbound |
| Vertiflex, INC. | $15.52 | 2019 | |
| Pfizer INC. | $11.63 | 2019 | |
| Electromed, INC. | $10.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Siew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.